Tumor Location Is Associated With the Prevalence of Braf And Pik3ca Mutations in Patients with Wild-Type Ras Colorectal Cancer: A Prospective Multi-Center Cohort Study in Japan

Taniguchi, Hiroya; Uehara, K.; Nakayama, Goro; Nakayama, Hiroshi; Aiba, Toshisada; Hattori, Norifumi; Kataoka, Masato; Nakano, Yuichi; Kawase, Yoshihisa; Okochi, Osamu; Matsuoka, Hiroshi; Utsunomiya, Setsuo; Shimizu, Eiji; Mori, Yoshinori; Umeda, Shinichi; Shikano, Takaaki; Kono, Koji; Tajika, Masahiro; Kadowaki, Shigenori; Muro, Kei; Yatabe, Yasushi

doi:10.1016/j.tranon.2020.100786

Cited by 10 publications

(13 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Overall, patients with left‐sided tumors have better survival with fewer metastases and are more often suited for curative resection 12 . Taniguchi et al 13 showed that right‐sided tumors are more likely to expose mutations of KRAS and BRAF , which correlate with unresectable liver metastases status, resistance to anti‐EGFR (epidermal growth factor receptor) antibody treatment, and negative prognostic outcome after liver resection. BRAF mutations occur in 32.3% of cases on the right‐sided colon.…”

Section: Methodsmentioning

confidence: 99%

“…A study on liver metastases samples of 124 patients with resected CLM revealed that high Ki‐67 expression may be an even stronger predictor of prognosis than KRAS; interestingly, patients with high Ki‐67 expression were more likely to present with synchronous CLM, high tumor burden, and preoperative CEA >200 ng/mL and less likely to undergo curative‐intent resection. On the contrary, a retrospective analysis with 98 liver resection patients reported conflicting results, where Ki‐67 overexpression was a positive prognostic factor of survival 36 . The explanation is believed to be found in the study design: the later study did include subjects that were chemotherapy‐naive, had multiple metastases, and a short time interval to metastasis, while the other did not differentiate 34 …”

Section: Methodsmentioning

confidence: 99%

“…34,35 BRAF and PIK3CA mutation is found to be more prevalent in rightsided CRC and is shown in the resistance to anti-EGFR therapy. 13,32…”

Section: Brafmentioning

confidence: 99%

“…On the contrary, a retrospective analysis with 98 liver resection patients reported conflicting results, where Ki-67 overexpression was a positive prognostic factor of survival. 36 The explanation is believed to be found in the study design: the later study did include subjects that were chemotherapy-naive, had multiple metastases, and a short time interval to metastasis, while the other did not differentiate. 34…”

Section: Ki-67mentioning

confidence: 99%

See 3 more Smart Citations

Biomarkers in colorectal liver metastases: Rising complexity and unknown clinical significance?

Fichtner‐Feigl

2021

Annals of Gastroent Surgery

View full text Add to dashboard Cite

Colorectal cancer (CRC) has 1.8 million cases globally and is the third most common cancer and ranks second by mortality. The incidence is rising due to socioeconomic developments, exposome changes, and the rise in age. 1 In all, 65% of CRC patients will develop metastases and 40% of those occur in the liver. Currently, the majority of CRC patients are assigned to curative surgery followed by adjuvant chemotherapy, which is predominantly determined by clinicopathologic features like primary tumor stage, carcinoembryonic antigen (CEA) level, nodal status, number and size of liver metastases, resection margin status, and the interval between primary tumor diagnosis and liver metastasis. 2,3 Notably, centers offering multidisciplinary treatment approaches including pathologists, radiologists, oncologists, and colorectal as well as liver surgeons show better survival rates than general hospitals or nonspecialized centers. 4 Over 50% of CRC patients will develop colorectal liver metastasis (CLM) and complete surgical removal still offers the best chance for long-term survival. 5 Nonetheless, one-third of CLM patients still succumb because of recurrent disease in the liver, which affects two-thirds of patients after resection. 6,7 Even modern multidisciplinary approaches that entail, e.g., two-stage hepatectomies after portal vein embolization, radiation, multiple ablation techniques for CLM (radiofrequency and microwave ablation), and expanding surgical techniques did not change this situation significantly until now. Currently, perioperative systematic therapy is suggested; however, a large randomized controlled trial by Nordlinger et al involving 364 patients showed no improvement in 5-year overall survival (OS) (51% vs 48%; P = .34) in

show abstract

Section: Methodsmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

“…34,35 BRAF and PIK3CA mutation is found to be more prevalent in rightsided CRC and is shown in the resistance to anti-EGFR therapy. 13,32…”

Section: Brafmentioning

confidence: 99%

Section: Ki-67mentioning

confidence: 99%

See 2 more Smart Citations

Biomarkers in colorectal liver metastases: Rising complexity and unknown clinical significance?

Fichtner‐Feigl

2021

Annals of Gastroent Surgery

View full text Add to dashboard Cite

show abstract

“…Shimada et al (2018) showed that the BRAF V600E mutation was found in 7 out of 98 samples. In addition, a study conducted by Taniguchi et al (2020) showed the percentage of BRAF V600E mutations was 34 (10.5%) out of 324 samples. Difference results were also found in the study conducted in Mexico, Latin America and the Caribbean population, which was 4% and 7.8%, respectively (Hernández-Sandoval et al 2020).…”

Section: Discussionmentioning

confidence: 99%

The prevalence of KRAS and BRAF mutation in colorectal cancer patients in Bali

Nyoman

Suksmarini

Pranata

et al. 2022

Indones. J. Biotechnol.

View full text Add to dashboard Cite

Mutations in the KRAS (Kirsten rat sarcoma viral oncogene homolog gene) and BRAF (v‐Raf murine sarcoma viral oncogene homolog B1) gene play a significant role in primary resistance to colorectal cancer therapy. Around 85‐90% of KRAS mutations in colorectal cancer occur in exon 2 (codon 12 and 13), whereas approximately 96% of BRAF mutations occur in exon 15 codon 600 (V600E). This study aimed to determine the prevalence and mutation characteristics of the KRAS and BRAF genes in colorectal cancer patients in Bali. The DNA was isolated from 44 formalin‐fixed paraffin‐embedded colorectal cancer samples which were stored in the Department of Pathology, Sanglah General Hospital in 2017. Detection of mutation was carried out by polymerase chain reaction (PCR) and direct sequencing. Out of 44 samples, only 27 were successfully amplified and sequenced. Our findings showed six samples (22.2%) with mutated KRAS at codons 12 and 13 (including two samples with G12D, one sample with G12V, and three samples with G13D). Interestingly, we found three samples (11.1%) of BRAF mutation, including two samples with V600E mutation and one with V600L mutation. Taken together, our results showed that KRAS and BRAF mutations were identified and occurred exclusively. Further studies are essential to identify the correlation of these mutations with colorectal cancer prognosis and response to chemotherapy

show abstract

Genomic Landscape of Primary Tumor Site and Clinical Outcome for Patients with Metastatic Colorectal Cancer Receiving Standard-of-Care Chemotherapy

et al. 2022

View full text Add to dashboard Cite

Tumor Location Is Associated With the Prevalence of Braf And Pik3ca Mutations in Patients with Wild-Type Ras Colorectal Cancer: A Prospective Multi-Center Cohort Study in Japan

Cited by 10 publications

References 28 publications

Biomarkers in colorectal liver metastases: Rising complexity and unknown clinical significance?

Biomarkers in colorectal liver metastases: Rising complexity and unknown clinical significance?

The prevalence of KRAS and BRAF mutation in colorectal cancer patients in Bali

Genomic Landscape of Primary Tumor Site and Clinical Outcome for Patients with Metastatic Colorectal Cancer Receiving Standard-of-Care Chemotherapy

Contact Info

Product

Resources

About